Eslicarbazepine acetate
- Generic Name
- Eslicarbazepine acetate
- Brand Names
- Aptiom, Zebinix
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16N2O3
- CAS Number
- 236395-14-5
- Unique Ingredient Identifier
- BEA68ZVB2K
- Background
Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body. E...
- Indication
Eslicarbazepine acetate is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
- Associated Conditions
- Partial-Onset Seizures
- Associated Therapies
- -
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 557
- Registration Number
- NCT00980746
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 20
- Registration Number
- NCT00971295
- Locations
- 🇵🇹
Human Pharmacology Unit (UFH)Section of Clinical Research (SIC), Department of Research & Development (DID), BIAL - Portela & Cª, SA,, Mamede do Coronado, Portugal
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 395
- Registration Number
- NCT00957047
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 253
- Registration Number
- NCT00957372
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures
- Conditions
- Interventions
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 402
- Registration Number
- NCT00957684
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Eslicarbazepine Acetate Monotherapy Long Term Study
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 274
- Registration Number
- NCT00910247
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Texas Neurology, PA, Dallas, Texas, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
- Conditions
- Interventions
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 14
- Registration Number
- NCT00900237
- Locations
- 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerpen, Antwerpen, Belgium
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
- Conditions
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 193
- Registration Number
- NCT00866775
- Locations
- 🇺🇸
Faculty of Physicians & Surgeons of Loma Linda University, Loma Linda, California, United States
🇺🇸Institute of Neurology and Neurosurgery at St. Bamabas, Suite 101, Livingston, New Jersey, United States
🇺🇸Massachusetts General Hospital Epilepsy Service - WACC, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.